Inclusion Criteria:  Sign informed consent voluntarily. Age ≥18 and ≤75 years old. Subjects with advanced solid tumors diagnosed by histology or cytology，whose desease progressed after standard treatment or have no standard treatment. Had at least one measurable lesion. ECOG≤1. Expected survival period ≥ 3 months.  Exclusion Criteria:  Any previous treatment with SHP-2 inhibitor. Symptomatic brain metastases. Subjects with thoracic/ascites fluid that need drainage or intervention. Subjects with not enough organ functional reserve at baseline, which met at least one of the following criteria： ANC<1.5×10^9/L PLT<100×10^9/L Hb<90g/L TBIL>1.5×ULN ALT, AST>2.5×ULN (without liver metastases) or ALT, AST>5×ULN (with liver metastases), Cr >1.5×ULN. With uncontrolled severe disease.